Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 14/20 | 0.65 |
| ▸ | CTSL | P07711 | 2/20 | 0.65 |
| ▸ | CTSB | P07858 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CTSG | P08311 | 1/20 | 0.65 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31406919 | 0.87 | CAPN1 (0.53) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL25901411 | 0.87 | CAPN1 (0.53) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL25314133 | 0.84 | CAPN1 (0.62) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL25314124 | 0.84 | CAPN1 (0.62) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL10863655 | 0.80 | CAPN1 (0.70) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL7400493 | 0.80 | CAPN1 (0.70) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL21396087 | 0.80 | CAPN1 (0.70) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL10863647 | 0.80 | CAPN1 (0.70) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL10863642 | 0.80 | CAPN1 (0.70) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL11194087 | 0.79 | CAPN1 (0.68) | CAPN1CTSLCTSBLMNACTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463445-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ?-GALACTOSIDASE ACTIVITY | DORPHAN S A (CH) | 2025-10-01 | — | — | EP | claimed |
| US-20250073198-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ß-GALACTOSIDASE ACTIVITY | DORPHAN S.A. (CH) | 2025-03-06 | — | — | US | claimed |
| EP-4463445-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ?-GALACTOSIDASE ACTIVITY | Dorphan S.A. (CH) | 2024-11-20 | — | — | EP | claimed |
| WO-2023135480-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED β-GALACTOSIDASE ACTIVITY | DORPHAN SA (CH) | 2023-07-20 | — | — | WO | claimed |
| EP-4463445-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ?-GALACTOSIDASE ACTIVITY | DORPHAN S A (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20250073198-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ß-GALACTOSIDASE ACTIVITY | DORPHAN S.A. (CH) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073198-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ß-GALACTOSIDASE ACTIVITY | MAN2B1, MANBA, GALC | CAPN1 362/4885CTSL 75/4885CTSB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.